Production (Stage)
AEON Biopharma, Inc.
AEON
$0.84
-$0.02-2.33%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.12M | 13.64M | 15.70M | 18.97M | 20.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.39M | 27.82M | 33.70M | 43.96M | 50.17M |
| Operating Income | -21.39M | -27.82M | -33.70M | -43.96M | -50.17M |
| Income Before Tax | 169.12M | 42.01M | 13.68M | -305.52M | -485.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 169.12 | 42.01 | 13.68 | -305.52 | -485.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 169.12M | 42.01M | 13.68M | -305.52M | -485.01M |
| EBIT | -21.39M | -27.82M | -33.70M | -43.96M | -50.17M |
| EBITDA | -21.30M | -27.73M | -33.60M | -43.86M | -50.07M |
| EPS Basic | 298.99 | 68.84 | 14.23 | -362.57 | -674.74 |
| Normalized Basic EPS | -7.85 | -74.34 | -72.69 | -97.67 | -103.43 |
| EPS Diluted | 298.42 | 68.27 | 13.96 | -362.57 | -674.74 |
| Normalized Diluted EPS | -7.84 | -74.33 | -72.69 | -97.67 | -103.43 |
| Average Basic Shares Outstanding | 5.63M | 2.16M | 2.12M | 2.41M | 3.80M |
| Average Diluted Shares Outstanding | 5.63M | 2.16M | 2.12M | 2.41M | 3.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |